MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:37Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:ACE inhibitors]]
			[[Category:Antihypertensives]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #195

2026-05-23T04:00:15Z

parser-claude batch MedTemplate pre-fill, Top 300 #195

New page

{{MedTemplate
| generic = Enalapril (and enalaprilat IV)
| brand = Vasotec, Vasotec IV, Epaned
| structure =
| classes = [[:Category:ACE_inhibitors|ACE inhibitor]], [[:Category:Antihypertensives|Antihypertensive]]
| uses = <vote slug="hypertension-use">Hypertension</vote>, <vote slug="heart-failure-use">Heart failure</vote>, <vote slug="asymptomatic-lvsd-use">Asymptomatic LV systolic dysfunction</vote>
| starting_dose = 5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF
| preparations = 2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat)
| fda_max = 40 mg/d
| pill_id =
| routes = Oral, IV
| onset = BP effect 1 hour; max at 4-6 hours
| duration = 12-24 hours
| halflife = ~11 hours (enalaprilat, the active metabolite)<ref name="vasotec-label">FDA Prescribing Information, Vasotec (enalapril maleate), Valeant/Bausch, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018998s080lbl.pdf</ref>
| bioavailability = ~60% (oral; food does not affect absorption)<ref name="vasotec-label" />
| pregnancy = '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection<ref name="vasotec-label" />
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="enalapril-mech-claim">Enalapril is an inactive prodrug hydrolyzed by hepatic carboxylesterases to enalaprilat, an ACE inhibitor that blocks conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and renal sodium retention.</vote> The IV form (enalaprilat) bypasses the prodrug activation step. Raises bradykinin, driving the characteristic dry cough and rare angioedema common across the ACE inhibitor class. The CONSENSUS (1987) and SOLVD (1991) trials made enalapril a cornerstone of evidence-based HFrEF therapy<ref name="vasotec-label" />.
}}

== References ==
<references />

Enalapril - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #195